Program
inaxaplin
Also written as “VX-147”, “IXP” and “Inaxaplin”.
Its studies are mostly in Glomerulosclerosis, Focal Segmental · Renal Insufficiency, led by Vertex Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vertex Pharmaceuticals | 61 open or running | phase 3since Mar 28, 2022 | Apr 7, 2020 | Jun 2, 2028phase 3 · NCT05312879 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 7, 2020First study: phase 2 study in Glomerulosclerosis, Focal SegmentalFirst studyNCT04340362 · 16 enrolled · United States, France, Puerto Rico and more
- Mar 28, 2022Phase 3 study in Proteinuric Kidney DiseaseNCT05312879 · 522 enrolled · United States, Belgium, Brazil and more
- May 9, 2023Phase 1 study in Renal InsufficiencyNCT05865171 · 16 enrolled · United States
- Jul 13, 2023Phase 1 study in Glomerulosclerosis, Focal SegmentalNCT05955872 · 21 enrolled · United States
- Jul 26, 2024Phase 1 study in Glomerulosclerosis, Focal SegmentalNCT06529796 · 36 enrolled · United States
- Jan 23, 2025Phase 2 study in Proteinuric Kidney DiseaseNCT06794996 · 42 enrolled · United States
Ahead
- Jun 2, 2028Primary completion: phase 3 study in Proteinuric Kidney DiseaseNCT05312879
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06794996Proteinuric Kidney Disease · United States | 2 | Completed | Jul 20, 2026 | 42 |
| NCT06529796Glomerulosclerosis, Focal Segmental · United States | 1 | Completed | Dec 20, 2024 | 36 |
| NCT05955872Glomerulosclerosis, Focal Segmental · United States | 1 | Completed | Sep 2, 2023 | 21 |
| NCT05865171Renal Insufficiency · United States | 1 | Completed | Jun 12, 2024 | 16 |
| NCT05312879Proteinuric Kidney Disease · United States, Belgium, Brazil and more | 3 | Active, not recruiting | Jun 2, 2028 | 522 |
| NCT04340362Glomerulosclerosis, Focal Segmental · United States, France, Puerto Rico and more | 2 | Completed | Nov 11, 2021 | 16 |
How it is read
Names in the registry
- “VX-147”, 3 entries
- “IXP”, 2 entries
- “Inaxaplin”, 1 entry
Codes read as this program: VX147.
Conditions, from the studies’ own filings
- Glomerulosclerosis, Focal Segmental, 3 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.